American College of Cardiology announces late-breaking clinical trials for ACC.26
The latest and greatest in cardiovascular science will be presented during a series of late-breaking, featured clinical research and investigative horizons sessions during ACC.26, the annual meeting of the American College of Cardiology (ACC) in New Orleans. The three-day event is scheduled to take place March 28-30.
"This is a massive meeting with more than 300 educational sessions and more than 1,300 speakers," meeting chair Katie L. Berlacher, MD, explained during a March 9 press conference.
This year's meeting has a record number of 60 late-breaking sessions, and overall had about 10,000 abstract submissions.
Berlacher and other physicians pointed to several highly anticipated presentations that will take place during during the press conference. These included:
• HI-PEITHO
• STEMI-DTU
• RECOVER-AUTONOMIC
• Al for Evaluating Cardiac Surgeons
• VESALIUS-CV
• GPS-CAD
• Discover INOCA
• Lung Impedance inHFpEF
• CHAMPION-AF
• SMART DECISION
• NOTIFY-HF
• GoFreshRx
Find more details on these sessions.
Late-breaker Sessions
Late-Breaking Clinical Trials I (Session 102)
Saturday, March 28, 9:30-10:30 AM CT, Main Tent, Great Hall
• Ultrasound-Facilitated Catheter-Directed Thrombolysis Vs Anticoagulation Alone For Acute Intermediate-High-Risk Pulmonary Embolism: Primary Results of the HI-PEITHO Randomized Clinical Trial. Presented by Stavros V. Konstantinides.
• Outcomes in Patients With Atrial Fibrillation Randomized to Receive Left Atrial Appendage Closure or Oral Anticoagulation: Primary Results of the CHAMPION-AF Clinical Trial. Presented by Saibal Kar.
• Primary Left Ventricular Unloading in Anterior ST-Segment Elevation Myocardial Infarction (STEMI) Without Cardiogenic Shock: Results From the STEMI-Door to Unload Randomized Clinical Trial. Presented by Daniel Burkhoff.
Late-Breaking Clinical Trials II (Session 105)
Saturday, March 28, 3:45–4:45 PM CT, Main Tent, Great Hall
• Kardinal: A Phase 2 Study of Tonlamarsen For the Treatment of Uncontrolled Hypertension. Presented by Luke Laffin.
• Evolocumab in Patients Without Significant Atherosclerosis: Results From VESALIUS-CV. Presented by Nicholas Marston.
• Intensive Low-Density Lipoprotein Cholesterol Targeting in Patients With Atherosclerotic Cardiovascular Disease. Presented by Byeong-Keuk Kim.
• DASH-Patterned Groceries to Reduce Blood Pressure Among Adults With Treated Hypertension: Results From the GoFreshRx Randomized Clinical Trial. Presented by Stephen Paul Juraschek.
Late-Breaking Clinical Trials III (Session 106)
Sunday, March 29, 8:30–9:30 AM CT, Main Tent, Great Hall
• Controlled Trial of High-Risk Coronary Intervention With Percutaneous Left Ventricular Unloading (CHIP-BCIS3). Presented by Divaka Perera.
• A Large-Scale, Global Randomized Trial of Coronary Physiology Derived From Conventional Angiography Compared With An Invasive Pressure Wire-Based Approach to Guide Percutaneous Coronary Intervention. Presented by Ajay J. Kirtane.
• A Randomized, Placebo-Controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention in Stable Angina- ORBITA-CTO Trial. Presented by Sarosh A. Khan.
• Fractional Flow Reserve or 3d-quantitative Coronary Angiography-Based Vessel-Ffr Guided Revascularization – The Fast Iii Trial. Presented by Joost Daemen.
Late-Breaking Clinical Trials IV (Session 107)
Sunday, March 29, 10:45–11:45 AM CT, Main Tent, Great Hall
• Spironolactone in the Treatment of Heart Failure. Presented by Frank Edelmann.
• Efficacy and Safety of Sotatercept in Combined Post- and Pre-Capillary Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction: Results From the Phase 2 Cadence Trial. Presented by Mardi Gomberg-Maitland.
• Lung Impedance-Guided Therapy in Heart Failure With Preserved Ejection Fraction: Results of a Randomized Clinical Trial. Presented by Michael Kleiner Shochat.
• Mavacamten in Symptomatic Adolescent Patients With Obstructive Hypertrophic Cardiomyopathy: Results From the Phase 3 Scout-HCM Trial. Presented by Joseph William Rossano.
Late-Breaking Clinical Trials V (Session 110)
Sunday, March 29, 4-5 PM CT, Main Tent, Great Hall
• Redo-Surgery Versus Transcatheter Valve-In-Valve For Mitral Bioprosthetic Dysfunction: The SURVIV Trial. Presented by Dimytri Siqueira.
• Transcatheter Aortic Valve Implantation Without Routine Percutaneous Coronary Intervention: A Randomized Controlled Trial. Presented by Michiel Voskuil.
• Protect The Head To Head Trial: Randomized Comparison of Emboliner Embolic Protection Catheter Vs. Sentinel Cerebral Protection System During Transcatheter Aortic Valve Replacement. Presented by Adam B. Greenbaum.
• Two-Year Outcomes After Transcatheter Tricuspid Repair Without Cross-over in the Randomized Tri-fr Trial. Presented by Erwan Donal.
Late-Breaking Clinical Trials VI (Session 111)
Monday, March 30, 8:30–9:30 AM CT, Main Tent, Great Hall
• Effects of a Food-is-medicine Intervention on Blood Pressure Among Black and Hispanic Adults With Hypertension in Healthy Food Priority Areas: The Thrive Pilot Trial. Presented by Oluwabunmi Ogungbe.
• Digoxin in Rheumatic Heart Disease: A Multi-Center, Randomized, Double Blind, Placebo-controlled Trial. Presented by Ganesan Karthikeyan.
• Discontinuation of Beta-blocker Therapy in Stabilized Patients After Acute Myocardial Infarction. Presented by Joo-Yong Hahn.
• Effect of Intensive Triglyceride Lowering With Olezarsen on Progression of Coronary Atherosclerosis: A Coronary CTA Substudy of The Essence-TIMI 73b Randomized Trial. Presented by Nicholas Marston.
Late-Breaking Clinical Trials VII (Session 112)
Monday, March 30, 10:45–11:45 AM CT, Main Tent, Great Hall
• Primary Efficacy and Safety Results From the Phase 3 Sirolimus-Coated Balloon For Infra-inguinal Peripheral Arterial Disease (SirPAD) Trial. Presented by Roberto Diletti.
• Intravascular Ultrasound Guidance For Complex High-Risk Indicated Procedures – The IVUS Chip Trial. Presented by Luca Testa.
• Intravascular Ultrasound-Guided Versus Angiography-Guided Percutaneous Coronary Intervention In Unprotected Left Main Coronary Artery Disease – The Optimal Trial. Presented by Shaoliang Chen.
• IVUS or Angiography Guidance for PCI in Complex Coronary Bifurcation Lesions. Presented by Stefano Barco.
Featured Clinical Research Sessions
Featured Clinical Research I (Session 201)
Saturday, March 28, Noon-1 PM CT, La Nouvelle B
• A Prospective Multicenter Registry to Define Coronary Vasomotor Disorders in Ischemia With Nonobstructive Coronary Arteries: Primary Results of Discover Inoca. Presented by Samit Shah.
• Impact of Ivabradine on Orthostatic Intolerance, Quality of Life and Heart Rate in Post-Covid Postural Orthostatic Tachycardia Syndrome (POTS): Results From the Recover-Autonomic Trial. Presented by Pam Taub.
• Coronary Optical Coherence Tomography and Cardiac Magnetic Resonance Imaging to Determine Sex Differences in Underlying Causes of Myocardial Infarction With No Obstructive Coronary Arteries. Presented by Harmony R. Reynolds.
• A Sham Controlled Randomized Trial Evaluating the Safety, Acceptability and Efficacy of Autonomic Neuromodulation Using Trans-Cutaneous Vagal Sensory Stimulation in Uncontrolled Hypertensive Patients. Presented by Ajay K. Gupta.
Featured Clinical Research II (Session 216)
Saturday, March 28, 1:30-2:30 PM CT, La Nouvelle B
• Effects of Tirzepatide Compared With Dulaglutide on Expanded Cardiorenal Outcomes. Presented by Steven E. Nissen.
• Prevalence and Clinical Impact of Hypercortisolism in Individuals With Resistant Hypertension: Primary Results From the Momentum Study. Presented by Deepak L. Bhatt.
• Reliability of CAC=0 to Exclude Coronary Plaque in Diverse Global Cohorts: A Global Probability Study of Coronary Artery Disease (GPS-CAD) Analysis. Presented by Lohendran Baskaran.
• Community-to-Clinic Linkage Implementation Program to Prevent Hypertension in Barbershops. Presented by Joseph E. Ravenell.
Featured Clinical Research III (Session 276)
Sunday, March 29, 12:15-1:15 PM CT, La Nouvelle B
• 10-year Follow-up of Clopidogrel Vs Aspirin Monotherapy in Stable Coronary Artery Disease After Percutaneous Coronary Intervention With Drug-eluting Stent. Presented by Hyo-Soo Kim.
• Role of Screening With Coronary Computed Tomography Angiography in Lipid Management in an Asymptomatic Chinese Population: A Community-Based, Parallel-Group, Open-Label, Randomized Clinical Trial (RESPECT2). Presented by Xiang Guo.
• Targeted Assessment in High-Risk Patients With Diabetes to Identify Undiagnosed Heart Failure. Presented by Daniel Taylor-Sweet.
Featured Clinical Research IV (Session 291)
Sunday, March 29, 1:45-2:45 PM CT, La Nouvelle B
• MUTTON-HF (Medically Utilized Tailored Traditional Foods to Optimize Nutrition in Heart Failure): A Randomized Controlled Trial of an Indigenous Food is Medicine Intervention. Presented by Lauren Eberly.
• NOTIFY-HF: A Randomized Pilot Trial of Patient-Facing Heartlogic Alerts in Heart Failure Patients. Presented by Joseph Assad.
• Automated Notifications to Improve Referral and Treatment of Severe Aortic Stenosis and Mitral Regurgitation: Outcomes From the Randomized Alert Trial. Presented by Wayne B. Batchelor.
• A Randomized Controlled Trial of a Novel Just-in-Time Adaptive Mobile Application Intervention to Reduce Sodium Intake and Blood Pressure in Patients With Hypertension. Presented by Michael Dorsch.
Featured Clinical Research V (Session 321)
Monday, March 30, 8:30-9:30 AM CT, La Nouvelle B
• The Role of Atrial Pacing Support in Cardiac Resynchronization Therapy: A Non-inferiority Randomized Trial. Presented by Mauro Biffi.
• Efficacy and Safety of BHB/HRS-1893 in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From A 12-week Phase 2 Study. Presented by Limei Wang.
• Two-Year Outcomes of Transcatheter Tricuspid Valve Replacement For Severe Tricuspid Regurgitation: The TRISCEND II Randomized Trial. Presented by Vinod H. Thourani,
• Prehospital Heparin Administration in Patients With STEMI Undergoing Primary PCI. Presented by Misa Fister.
Investigative Horizons Sessions
Investigative Horizons I (Session 336)
Monday, March 30, 10:45-11:45 AM CT, La Nouvelle B
• Efficacy and Safety of Enlicitide Decanoate, An Oral Macrocyclic Peptide Inhibitor of PCSK9, Compared With Bempedoic Acid, Ezetimibe, Or Bempedoic Acid Co-Administered With Ezetimibe in Statin-Treated Adults With Hypercholesterolemia: Phase 3 CORALreef AddOn Trial. Presented by Alberico L. Catapano.
• Anti-Inflammatory Actions and Safety of the NLRP3 Inhibitor VTX3232 Alone or in Combination With Semaglutide in Participants With Obesity: A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. Presented by Peter Libby.
• Effect of Anti-Fibrotic Therapy on Regression of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients With High Fibrotic Burden: The Reduce-MFA DZHK 25-trial. Presented by Miriam Puls.
• Prospective Multi-Center Clinical Trial of Artificial-Intelligence Analysis of Retinal Images For Identifying Elevated Atherosclerotic Cardiovascular Risk. Presented by Michael V. McConnell.
Investigative Horizons II (Session 351)
Monday, March 30, 12:15-1:15 PM CT, La Nouvelle B
• Safety and Preliminary Efficacy of AAVrh.10hPKP2 (LX2020) Gene Therapy in PKP2- Arrhythmogenic Cardiomyopathy. Presented by Ronald Crystal.
• Effect of Financial Support on Quality of Life and Medication Adherence Among Low-Income Patients Following Hospitalization For Heart Failure: The FUND-HF Trial. Presented by Ambarish Pandey.
• Adaptive AI For Cardiovascular Event Adjudication: Identifying Cardiovascular Events Across Changing Definitions in the Odyssey and Euclid Trials. Presented by Sreekanth Vemulapalli.
• Artificial Intelligence Based Screening For Structural Heart Disease Using An ECG: Results From the PREVUE-VALVE Study. Presented by Timothy Poterucha.
Investigative Horizons III (Session 366)
Monday, March 30, 1:45-2:45 PM CT, La Nouvelle B
• Artificial Intelligence Model For Evaluating Surgical Techniques of Cardiac Surgeons. Presented by Xin Yuan.
• The Npr1 Agonist Xxb750 In Heart Failure. Presented by Scott Solomon.
• Safety And Preliminary Efficacy Of AAVrh.10hPKP2 (LX2020) Gene Therapy In PKP2- Arrhythmogenic Cardiomyopathy. Presented by Victoria Parikh.
• Durability of Enlicitide For Lipid Lowering: On-treatment Analysis of Data From CORALreef Lipids and CORALreef HeFH Trials. Presented by Ann Marie Navar.
• Long-Term Survival Benefits and Disease Stabilization With Acoramidis In Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM). Presented by Prem Soman.
Dave Fornell has covered healthcare for more than 17 years, with a focus in cardiology and radiology. Fornell is a 5-time winner of a Jesse H. Neal Award, the most prestigious editorial honors in the field of specialized journalism. The wins included best technical content, best use of social media and best COVID-19 coverage. Fornell was also a three-time Neal finalist for best range of work by a single author. He produces more than 100 editorial videos each year, most of them interviews with key opinion leaders in medicine. He also writes technical articles, covers key trends, conducts video hospital site visits, and is very involved with social media. E-mail: [email protected]